Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1.

The Epstein-Barr virus (EBV) nuclear antigen EBNA-1 is essential for viral genome maintenance in vitro and may be the only EBV protein expressed by the majority of latently infected cells in vivo. EBNA-1 may therefore be critical to the evasion of host immunity which allows persistent infection. EBNA-1 includes a polymorphic internal repeat domain of unknown significance and unique regions which mediate all known functional activities and which have hitherto been assumed to be conserved between strains. Monoclonal antibodies were generated using a construct based on EBNA-1 of the prototype B95-8 strain, deleted for the repeat domain. These antibodies showed a limited profile of recognition of EBNA-1 in common laboratory EBV+ cell lines by immunoprecipitation and immunostaining. The observed antigenic heterogeneity also extended to spontaneously transformed B lymphoblastoid cell lines (LCLs) representing viral isolates circulating within US and UK populations. DNA fragments spanning the C-terminal unique domain of EBNA-1 from eleven spontaneous LCLs were amplified by polymerase chain reaction for sequencing, which directly demonstrated extensive and unexpected variability between diverse type 1 EBV isolates. The resulting polymorphism affects most of the putative MHC Class I binding epitopes which could be identified within this region using published sequence motifs, and influences MHC binding by variants of at least one such peptide in the processing mutant cell line T2. These findings could be related to the apparent lack of recognition of EBNA-1 by cytotoxic T lymphocytes.

[1]  A Sette,et al.  Definition of specific peptide motifs for four major HLA-A alleles. , 1994, Journal of immunology.

[2]  S. Sengupta,et al.  Heterogeneity within the Epstein-Barr virus nuclear antigen 2 gene in different strains of Epstein-Barr virus. , 1994, The Journal of general virology.

[3]  S. Burrows,et al.  Potential antigenic targets on Epstein-Barr virus-associated tumours and the host response. , 1994, Ciba Foundation symposium.

[4]  I. Ernberg,et al.  Detection of multiple 'Ebnotypes' in individual Epstein-Barr virus carriers following lymphocyte transformation by virus derived from peripheral blood and oropharynx. , 1994, The Journal of general virology.

[5]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[6]  William S. Lane,et al.  Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle , 1992, Nature.

[7]  E. Kieff,et al.  Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies , 1992, The Journal of experimental medicine.

[8]  G. Hayward,et al.  Binding of EBNA-1 to DNA creates a protease-resistant domain that encompasses the DNA recognition and dimerization functions , 1992, Journal of virology.

[9]  J. Arrand,et al.  Detection of EBV DNA in post‐nasal space biopsy tissue from asymptomatic EBV‐seropositive individuals , 1992, Journal of medical virology.

[10]  J. Hearing,et al.  Interaction of Epstein-Barr virus nuclear antigen 1 with the viral latent origin of replication , 1992, Journal of virology.

[11]  T. Honma,et al.  The domain of Epstein-Barr virus nuclear antigen 1 essential for binding to oriP region has a sequence fitted for the hypothetical basic-helix-loop-helix structure. , 1991, Virology.

[12]  H. Cen,et al.  Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4 , 1991, Journal of virology.

[13]  D. Cooper,et al.  Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. , 1990, The Journal of infectious diseases.

[14]  B. Sugden,et al.  The average number of molecules of Epstein-Barr nuclear antigen 1 per cell does not correlate with the average number of Epstein-Barr virus (EBV) DNA molecules per cell among different clones of EBV-immortalized cells , 1990, Journal of virology.

[15]  J. Yates,et al.  Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus , 1989, Journal of virology.

[16]  B. Sugden,et al.  A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection , 1989, Journal of virology.

[17]  L. Young,et al.  Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV types A and B , 1989, Journal of virology.

[18]  M. Rowe,et al.  Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. , 1988, The Journal of general virology.

[19]  G. Miller,et al.  Fragment length polymorphisms among independent isolates of Epstein-Barr virus from immunocompromised and normal hosts. , 1988, The Journal of infectious diseases.

[20]  L. Young,et al.  Differences in B cell growth phenotype reflect novel patterns of Epstein‐Barr virus latent gene expression in Burkitt's lymphoma cells. , 1987, The EMBO journal.

[21]  M. Epstein,et al.  A re‐examination of the epstein‐barr virus carrier state in healthy seropositive individuals , 1985, International journal of cancer.